D-0085-2024 Class III Terminated
FDA drug recall D-0085-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 20, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Aug 16, 2024). Affected quantity: 480 100-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 8, 2023
- Initiation Date
- Oct 20, 2023
- Termination Date
- Aug 16, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 480 100-count bottles
Product description
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
Nationwide in the USA
Code information
Lot# 17212352, Exp 11/31/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0085-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026